TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35506381

Group type: EXPERIMENTAL
Intervention: 38% silver diamine fluoride (SDF)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Atraumatic restorative treatment (ART)
Number of subjects: 190
Study: 32367748

Group type: EXPERIMENTAL
Intervention: Baihe Gujin decoction combined with anti-tuberculosis therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Anti-tuberculosis treatment
Number of subjects: 100
Study: 34289275

Group type: EXPERIMENTAL
Intervention: Pimavanserin
Number of subjects: 351

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 351
Study: 32102910

Group type: EXPERIMENTAL
Intervention: Very low nicotine content (VLNC) cigarettes
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normal nicotine cigarettes
Number of subjects: 16
Study: 36221062

Group type: EXPERIMENTAL
Intervention: EC skin test
Number of subjects: 14579

Group type: COMPARATOR
Intervention: TST
Number of subjects: 14579
Study: 33165125

Group type: EXPERIMENTAL
Intervention: Methamphetamine use
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Higher time‐varying sCD14 levels
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Time‐varying detectable viral loads
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Time‐varying reactive urine toxicology results for stimulants
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Greater proviral HIV DNA at baseline
Number of subjects: 110
Study: 32844885

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 106

Group type: COMPARATOR
Intervention: Val/Val genotype
Number of subjects: 106
Study: 36231316

Group type: EXPERIMENTAL
Intervention: 12-week school-based physical activity intervention (24 sessions, 2 sessions/week, 60 min/session)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study: 33951415

Group type: EXPERIMENTAL
Intervention: Alirocumab (150 mg biweekly subcutaneous)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 32197105

Group type: EXPERIMENTAL
Intervention: TAK-003
Number of subjects: 20099

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20099
Study: 34378087

Group type: EXPERIMENTAL
Intervention: CVnCoV 2μg, n=47
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: CVnCoV 4μg, n=48
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: CVnCoV 6μg, n=46
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: CVnCoV 8μg, n=44
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: CVnCoV 12μg, n=28
Number of subjects: 245

Group type: COMPARATOR
Intervention: Placebo, n=32
Number of subjects: 245
Study: 33187076

Group type: EXPERIMENTAL
Intervention: Group-based progressive strength training program (3 days per week for 8 weeks)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Group-based progressive strength training program
Number of subjects: 85
Study: 35978289

Group type: EXPERIMENTAL
Intervention: Multi-faceted exercise intervention (thrice weekly aerobic and progressive resistance training, reducing sedentary time by 30 min)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Multi-faceted exercise intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study: 33935256

Group type: EXPERIMENTAL
Intervention: Intracorporeal anastomosis (IA)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Extracorporeal anastomosis
Number of subjects: 168
Study: 32763640

Group type: EXPERIMENTAL
Intervention: ICU diary intervention with psychoeducation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Education alone (control group)
Number of subjects: 60
Study: 35940529

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 35410769

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 50

Group type: COMPARATOR
Intervention: No tDCS
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 50
Study: 33759069

Group type: EXPERIMENTAL
Intervention: PEX glaucoma
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: POAG
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: POAG and PEX glaucoma
Number of subjects: 34

Group type: COMPARATOR
Intervention: POAG and Control
Number of subjects: 34
Study: 35107399

Group type: EXPERIMENTAL
Intervention: Mat Pilates (3 times/week, 60 min session)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (relaxation activities every two weeks)
Number of subjects: 43
Study: 33276816

Group type: EXPERIMENTAL
Intervention: Nurse-Family Partnership’s home visiting program
Number of subjects: 0
Study: 34021314

Group type: EXPERIMENTAL
Intervention: EC skin test at 1.0 μg/0.1 mL
Number of subjects: 873

Group type: EXPERIMENTAL
Intervention: EC skin test at 0.5 μg/0.1 mL
Number of subjects: 873

Group type: COMPARATOR
Intervention: T-SPOT.TB test
Number of subjects: 873

Group type: EXPERIMENTAL
Intervention: EC skin test among BCG vaccinated participants
Number of subjects: 873

Group type: EXPERIMENTAL
Intervention: EC skin test
Number of subjects: 873
Study: 34066126

Group type: EXPERIMENTAL
Intervention: ADHD
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Cyclothymic disorder
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Both conditions (ADHD and cyclothymic disorder)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Non-comorbid cyclothymic patients
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Comorbid patients with both conditions
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Cyclothymic patients without ADHD
Number of subjects: 165

Group type: COMPARATOR
Intervention: ADHD patients without cyclothymia
Number of subjects: 165
Study: 32572510

Group type: EXPERIMENTAL
Intervention: Periareolar dermis release
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control (no periareolar dermis release)
Number of subjects: 39
Study: 36237122

Group type: EXPERIMENTAL
Intervention: Egg-breakfast
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cereal-breakfast
Number of subjects: 30
Study: 33334939

Group type: EXPERIMENTAL
Intervention: Low-dose theophylline 100 mg twice daily plus low-dose oral prednisone 5 mg once daily
Number of subjects: 1670

Group type: EXPERIMENTAL
Intervention: Low-dose theophylline 100 mg twice daily plus placebo
Number of subjects: 1670

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1670

Group type: EXPERIMENTAL
Intervention: Theophylline plus prednisone versus pooled theophylline plus placebo and placebo
Number of subjects: 1670

Group type: EXPERIMENTAL
Intervention: Theophylline plus placebo versus placebo
Number of subjects: 1670

Group type: EXPERIMENTAL
Intervention: Theophylline plus prednisone versus placebo
Number of subjects: 1670
Study: 33584074

Group type: EXPERIMENTAL
Intervention: Quiklean® (32-tablet sodium phosphate)
Number of subjects: 442

Group type: COMPARATOR
Intervention: Klean‐Prep/Dulcolax® (2-L polyethylene glycol/bisacodyl)
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Quiklean®
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Quiklean® and Klean‐Prep/Dulcolax®
Number of subjects: 442
Study: 32250536

Group type: EXPERIMENTAL
Intervention: Insulin degludec (degludec)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin glargine 100 units/mL (glargine U100)
Number of subjects: 0
Study: 34647404

Group type: EXPERIMENTAL
Intervention: Tirzepatide 5 mg (weeks 1-8)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Tirzepatide 10 mg (2.5 mg weeks 1-2; 5 mg weeks 3-4; 10 mg weeks 5-8)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Tirzepatide 15 mg (5 mg weeks 1-2; 10 mg weeks 3-6; 15 mg weeks 7-8)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Tirzepatide 5 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Tirzepatide 10 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Tirzepatide 15 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 33911100

Group type: EXPERIMENTAL
Intervention: NMES with 50 Hz
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: NMES with 35 Hz
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 69
Study: 36086927

Group type: EXPERIMENTAL
Intervention: Subcision plus SVF
Number of subjects: 10

Group type: COMPARATOR
Intervention: Subcision alone
Number of subjects: 10
Study: 32180266

Group type: EXPERIMENTAL
Intervention: Wiping once with pressure ≥50 mmHg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Wiping twice with pressure ≥40 mmHg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Wiping thrice with pressure ≥10 mmHg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Wiping once with pressure ≥5 mmHg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Wiping with at least 10 mmHg or more three times
Number of subjects: 50
Study: 34979510

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) surgery
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no surgery)
Number of subjects: 38
Study: 33040678

Group type: EXPERIMENTAL
Intervention: Mental Imagery (MI) training for 30 min/day for 5 days
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Mental Imagery (MI) training
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study: 34059080

Group type: EXPERIMENTAL
Intervention: Intra-articular injection of umbilical cord-derived Wharton's jelly (WJ)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Hyaluronic acid (HA)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Saline (placebo control)
Number of subjects: 168
Study: 35948970

Group type: EXPERIMENTAL
Intervention: We Can Quit intervention with free nicotine replacement therapy (NRT)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: We Can Quit intervention with group-based support facilitated by trained lay local community facilitators (CFs)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: We Can Quit intervention with free NRT
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Support provided by pharmacists
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Future definitive trial (DT) observational fidelity assessments
Number of subjects: 21
Study: 33661694

Group type: EXPERIMENTAL
Intervention: Video intervention that addressed avoidance and promoted healthy coping strategies
Number of subjects: 235

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 235
Study: 32446306

Group type: EXPERIMENTAL
Intervention: Fenofibrate treatment group (n = 28)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (n = 28)
Number of subjects: 56
Study: 35181523

Group type: EXPERIMENTAL
Intervention: Segmental resection
Number of subjects: 55

Group type: COMPARATOR
Intervention: Nodule excision via shaving or disk excision
Number of subjects: 55
Study: 34109778

Group type: EXPERIMENTAL
Intervention: Vitamin D3 buccal spray (2000 U, n=30) for six weeks
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Oral drops (2000 U, n=30) for six weeks
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Single oral dose (300,000 U, n=30)
Number of subjects: 90
Study: 33147541

Group type: EXPERIMENTAL
Intervention: 80 mg nano-curcumin for two months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo for two months
Number of subjects: 40
Study: 34606932

Group type: EXPERIMENTAL
Intervention: Coverall PPE removal
Number of subjects: 60

Group type: COMPARATOR
Intervention: Gown PPE removal
Number of subjects: 60
Study: 35182352

Group type: EXPERIMENTAL
Intervention: multidomain lifestyle intervention
Number of subjects: 1260

Group type: COMPARATOR
Intervention: regular health advice
Number of subjects: 1260
Study: 33677072

Group type: EXPERIMENTAL
Intervention: Promoting Resilience in Stress Management (PRISM) intervention
Number of subjects: 0
Study: 36174766

Group type: EXPERIMENTAL
Intervention: F2 group (etch-mineralizing solution with 10 mg/ml sodium fluoride)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (35% phosphoric acid gel treatment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental groups (F1, F2, F3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental groups
Number of subjects: 0
Study: 32524768

Group type: EXPERIMENTAL
Intervention: Antidepressant drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visualization methods
Number of subjects: 0
Study: 32101792

Group type: COMPARATOR
Intervention: No fluid (NF)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Water (WAT)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Carbohydrate-electrolyte solution (CES)
Number of subjects: 11
Study: 35843957

Group type: EXPERIMENTAL
Intervention: CAREDYNE Shield (intervention group)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nanoseal (control group)
Number of subjects: 24
Study: 32524850

Group type: EXPERIMENTAL
Intervention: Brief multimodal online intervention targeting illness representations about skin cancer
Number of subjects: 509
Study: 35500846

Group type: EXPERIMENTAL
Intervention: Micro-infusion pump at 2 ml/h without accompanying fluid (Observation group)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Micro-infusion pump at 2 ml/h with normal saline (Control group)
Number of subjects: 215
Study: 34055118

Group type: EXPERIMENTAL
Intervention: Orofacial pain assessment using Visual Analogue Scale (VAS)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Dental health status measured by DMFT
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Oral health status measured by OHI-S
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Psychological status assessed using Generalized Anxiety Disorder Scale
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Psychological status assessed using Impact of Events Scale
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Brushing frequency and dental visits
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Plaque accumulation measured by OHI-S
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Employment status and severity of burn
Number of subjects: 90
Study: 32053557

Group type: EXPERIMENTAL
Intervention: Low tidal volume ventilation (6.5 ± 1.8 ml/kg predicted body weight)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Intermediate tidal volume ventilation (9.5 ± 1.6 ml/kg predicted body weight)
Number of subjects: 42
Study: 35491787

Group type: EXPERIMENTAL
Intervention: PBM therapy (real light therapy)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Sham light therapy
Number of subjects: 58
Study: 35786297

Group type: EXPERIMENTAL
Intervention: Chiropractic spinal manipulative therapy and exercise
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Self-care or self-management coping styles
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Coping strategies
Number of subjects: 50
Study: 35189818

Group type: EXPERIMENTAL
Intervention: Artesunate–amodiaquine (AS-AQ)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Artemether–lumefantrine (AL)
Number of subjects: 242
Study: 32036671

Group type: EXPERIMENTAL
Intervention: Interdisciplinary outpatient palliative care
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 60
Study: 36309744

Group type: EXPERIMENTAL
Intervention: Electronic pillbox intervention with pre-filled weekly blister pack medication trays, alarms, detection of pill removal, alerts to patients or caregivers, adherence reports, and pharmacist outreach for missed doses.
Number of subjects: 0
Study: 33374554

Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 24

Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 24
Study: 34474731

Group type: EXPERIMENTAL
Intervention: Metoprolol (15 mg daily for 3 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 20
Study: 33734782

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral substance use treatment (standard)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral substance use treatment (culturally accommodated)
Number of subjects: 70
Study: 32119656

Group type: EXPERIMENTAL
Intervention: Bayesian network analysis (BN) with two directional anchors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bayesian network analysis (BN) with a single directional anchor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bayesian network analysis (BN) with no directional anchor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bayesian network analysis (BN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mendelian randomization (MR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bayesian network analysis (BN) incorporating genetic anchors
Number of subjects: 0
Study: 34023938

Group type: EXPERIMENTAL
Intervention: Wild blueberry (WBB) drink intervention (766 mg total polyphenols; 253 mg anthocyanins; equivalent to 240 g fresh blueberries per day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Wild blueberry (WBB) drink intervention
Number of subjects: 15
Study: 32739320

Group type: EXPERIMENTAL
Intervention: Reduced dose to the posterior prostate and surrounding regions in RADAR and RT01 patients
Number of subjects: 683

Group type: EXPERIMENTAL
Intervention: Reduced dose to the seminal vesicle region in RADAR intermediate-risk patients
Number of subjects: 683

Group type: COMPARATOR
Intervention: Control group from CHHiP trial
Number of subjects: 683
Study: 35470400

Group type: EXPERIMENTAL
Intervention: Sleep
Number of subjects: 30

Group type: COMPARATOR
Intervention: Total sleep deprivation
Number of subjects: 30
Study: 35750784

Group type: EXPERIMENTAL
Intervention: Virtual simulation experiment teaching platform
Number of subjects: 56

Group type: COMPARATOR
Intervention: Traditional teaching method
Number of subjects: 56
Study: 36088627

Group type: EXPERIMENTAL
Intervention: Intralesional vitamin D3
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intralesional measles, mumps, and rubella (MMR) vaccine
Number of subjects: 100
Study: 34097368

Group type: EXPERIMENTAL
Intervention: Rituximab (1000 mg on days 1, 15, 168, and 182)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Mycophenolate mofetil (2 g per day)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 135

Group type: COMPARATOR
Intervention: Mycophenolate mofetil
Number of subjects: 135
Study: 32096120

Group type: COMPARATOR
Intervention: Mild illness
Number of subjects: 471

Group type: COMPARATOR
Intervention: Maximal (100%) burst suppression burden
Number of subjects: 471

Group type: COMPARATOR
Intervention: High cumulative propofol dose (1316 mg/kg)
Number of subjects: 471

Group type: COMPARATOR
Intervention: Propofol exposure
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Burst suppression
Number of subjects: 471
Study: 34340096

Group type: EXPERIMENTAL
Intervention: Shangliao point injection combined with epidural analgesia
Number of subjects: 93

Group type: COMPARATOR
Intervention: Epidural analgesia
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Shangliao point injection
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Epidural analgesia and saline injection
Number of subjects: 93
Study: 36231542

Group type: EXPERIMENTAL
Intervention: Web-based personalized intervention based on artificial intelligence
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard primary health care by nurses
Number of subjects: 0
Study: 33431900

Group type: EXPERIMENTAL
Intervention: Prediction model of live birth for ART patients
Number of subjects: 0
Study: 32593779

Group type: EXPERIMENTAL
Intervention: Low dose aspirin (150 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35032437

Group type: EXPERIMENTAL
Intervention: Nivolumab plus cabozantinib
Number of subjects: 651

Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 651
Study: 32926259

Group type: EXPERIMENTAL
Intervention: Transinguinal preperitoneal repair with modified Kugel patch (MK)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Lichtenstein repair (LR)
Number of subjects: 200
Study: 32641101

Group type: EXPERIMENTAL
Intervention: Bortezomib (up to 3 cycles, each 21 days with 4 subcutaneous applications)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (up to 3 cycles, each 21 days with 4 subcutaneous applications)
Number of subjects: 50
Study: 36222880

Group type: EXPERIMENTAL
Intervention: 10-mg dose of amiloride
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 33716004

Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 744

Group type: COMPARATOR
Intervention: Control (no statin use)
Number of subjects: 744
Study: 36282602

Group type: EXPERIMENTAL
Intervention: Aerosol PPE
Number of subjects: 16
Study: 32473592

Group type: EXPERIMENTAL
Intervention: Tethered swimming (TS)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (moderate pace swimming)
Number of subjects: 14
Study: 32543054

Group type: EXPERIMENTAL
Intervention: EPOCH interventions targeting obesity-related behaviours; specific interventions not detailed.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delivery features of EPOCH interventions; specific details not provided.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behaviour change techniques (BCTs) used in EPOCH interventions; specific techniques listed.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recommendations from interview analyses; specific recommendations not detailed.
Number of subjects: 0
Study: 34922807

Group type: EXPERIMENTAL
Intervention: Rehabilitation Group (RG) - five days of intensive exercise program and early ambulation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Mobilization Group (MG) - five days of standard gait training and early ambulation
Number of subjects: 40
Study: 33536055

Group type: EXPERIMENTAL
Intervention: Whole-plant cannabis extract (BOL‐DP‐O‐01‐W) containing cannabidiol and Δ9‐tetrahydrocannabinol at a 20:1 ratio
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Whole-plant cannabis extract (BOL‐DP‐O‐01‐W)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 35605176

Group type: EXPERIMENTAL
Intervention: Venetoclax-rituximab (VenR)
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Venetoclax-rituximab (VenR) with undetectable minimal residual disease (uMRD) at end of treatment (EOT)
Number of subjects: 389